A Study to Assess the Relative Bioavailability Three New Formulations of Telaprevir in Healthy Subjects
| Status: | Archived |
|---|---|
| Conditions: | Hepatitis |
| Therapuetic Areas: | Immunology / Infectious Diseases |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | January 2012 |
| End Date: | August 2012 |
| Contact: | Medical Information |
| Email: | medicalinfo@vrtx.com |
A Two-Part, Phase 1, Randomized, Open-Label, Crossover Study to Evaluate the Relative Bioavailability of 3 Novel Oral Formulations of Telaprevir Relative to Incivek 375-mg Tablets When Administered as a Single 1125-mg Dose to Healthy Subjects
The purpose of this study is to evaluate the relative bioavailability, safety, and
tolerability of 3 new formulations of telaprevir relative to the Incivek 375-mg tablets.
We found this trial at
2
sites
